ClinicalTrials.gg
RecruitingNCT07403487Updated Sep 10, 2026

Phase II Trial of RC1416 Injection in Asthma

A Phase 2 interventional study of RC1416 and RC1416 Placebo in Moderate to Severe Asthma, sponsored by Nanjing RegeneCore Biotech Co., Ltd.. Recruiting at 44 sites in China. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-09-10.

Sponsored by Nanjing RegeneCore Biotech Co., Ltd. · Phase 2, Interventional, and Treatment

From the registry’s dates

  • Started Mar 2026; still recruiting 8 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
195
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 251 studies in Asthma with a site in China — 87 open to participants now, 96 under way, 15 of them phase 3. Asthma · China.

Planned enrollment
100th of 182
195 · median 203
Started
2026
with 19 others
Phase 2
39 of 251
19 open now
Primary completion
2027-10
later than 59 of 95 live
Registered
229th of 251
by date

Among the 251 studies in Asthma with a site in China, this one is the 100th largest by planned enrollment of the 182 interventional ones that give a count, is one of 20 that started in 2026, is one of 39 in phase 2, reaches primary completion later than 59 of the 95 other live ones, and was the 229th registered.

Asthma

4,848 studies on the registry are indexed under Asthma; 605 are open to participants now.

Browse Asthma studies →

Open to participants now

87 of the 251 studies in Asthma with a site in China are open now. Recruiting first, the newest first:

81 more — sign in →

All 87 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 417 Asthma studies recruiting now, 140 (34%) set no upper age limit and 205 (49%) stop at 75 or younger; 147 take children under 18; 105 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 251 studies in Asthma with a site in China, or all of them as a file.
02

Study summary

This study is a phase II study of RC1416 in subjects with severe uncontrolled asthma. The purpose of the study is to evaluate efficacy and safety of RC1416 in subjects with severe uncontrolled asthma.

Read the detailed description

RC1416 is a bispecific homodimer nanobody .It is being developed by Nanjing RegeneCore Biotech Co., Ltd. as a potential therapy for asthma. A total 195 severe uncontrolled asthma subjects will be enrolled in three groups to access the efficacy and safety of RC1416.

03

Conditions studied

  • Moderate to Severe Asthma

Browse trials for

04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male or female aged 18 and 75 years.
  • Diagnosed with asthma for at least 1 year, and the current disease status meets the diagnostic criteria of the 2024 GINA guidelines.
  • Have received medium-to-high dose ICS therapy for at least 3 consecutive months prior to screening, and maintained a stable treatment regimen and dose for ≥1 month prior to baseline.
  • Pre-bronchodilator (FEV1) measurement ≤80% of the predicted normal value at both the screening and baseline visits.
  • Asthma Control Questionnaire-6 (ACQ-6) score ≥1.5 at both the screening and baseline visits.
  • Must have experienced ≥1 severe asthma exacerbation event within the 12 months prior to screening.
  • Positive bronchodilator reversibility test.

Exclusion criteria

Exclusion Criteria:

  • Individuals with a known history of allergy to the product or its .
  • Clinically diagnosed with (COPD) or other lung diseases that may impair lung function .
  • Experienced a severe asthma exacerbation event from within 1 month prior to screening until before dosing.
  • Used systemic within 1 week prior to screening.
  • Had a pulmonary or other site infection requiring intravenous antibiotics, antifungals, or antivirals from within 1 month prior to screening until before dosing.
  • Used traditional Chinese medicine with anti-asthmatic effects within 1 month prior to screening.
  • Underwent major surgery within 8 weeks prior to screening or plans to undergo major surgery during the study period.
  • With a history of within the past 5 years .
  • Active or incompletely treated tuberculosis
  • Used biologic/systemic /immunomodulators within 12 weeks or 5 half-lives prior to screening.
  • Diagnosed active parasitic infection; suspected parasitic infection or high risk of infection.
  • Abnormal 12-lead (ECG) at screening. The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial
Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

FEV1

From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Investigator, Outcomes assessor)
Enrollment
195 participants (estimated)

Study arms

  • Experimental
    RC1416

    Drug: RC1416

  • Placebo comparator
    RC1416 Placebo

    Drug: RC1416 Placebo

Interventions

  • DrugRC1416

    There are two doses in this part. Each subjects will receive the drug by subcutaneous injection.

  • DrugRC1416 Placebo

    Each subjects will receive the placebo by subcutaneous injection

06

What researchers measure

Primary outcomes

  1. Pre-bronchodilator (Pre-BD) forced expiratory volume in 1 Second (FEV1)

    Mean change from baseline in Pre-BD forced expiratory volume in 1 Second (FEV1)

    Time frame: During 32 weeks

Secondary outcomes

  1. Severe asthma exacerbation

    Severe asthma exacerbation events, Time to the first asthma exacerbation

    Time frame: During 32 weeks

  2. Pre-BD FEV1

    Time frame: During 32 weeks

  3. Morning and evening peak expiratory flow (PEF)

    Mean change from baseline of absolute value and percentage

    Time frame: During 32 weeks

  4. forced vital capacity (FVC)

    Mean change from baseline of absolute value and percentage

    Time frame: During 32 weeks

  5. Forced mid-expiratory flow (FEF25-75%) before bronchodilator (BD)

    Mean change from baseline of absolute value and percentage

    Time frame: During 32 weeks

  6. Asthma loss of control (LOAC)

    Asthma loss of control (LOAC) events, Time to the first Asthma loss of control

    Time frame: During 32 weeks

  7. Acute exacerbation of severe asthma - induced hospitalization or Emergency Department visit

    Acute exacerbation of severe asthma - induced hospitalization or Emergency Department visit events

    Time frame: During 32 weeks

  8. Asthma Control Questionnaire-6 (ACQ-6) score

    Mean change Mean change from baseline. The proportion of trial participants with a reduction of ≥0.5 points from baseline

    Time frame: During 32 weeks

  9. Asthma Quality of Life Questionnaire (AQLQ-S) score

    Mean change from baseline

    Time frame: During 32 weeks

  10. weekly Asthma Symptom Diary (ASD) score

    Mean change in mean weekly from baseline

    Time frame: During 32 weeks

  11. Rescue medication

    Mean change in mean weekly from baseline

    Time frame: During 32 weeks

  12. Adverse Events

    Time frame: During 32 weeks

  13. Pharmacokinetics

    trough concentration

    Time frame: During 32 weeks

  14. Pharmacodynamics

    mean changes of Pharmacodynamic Parameter from baseline

    Time frame: During 32 weeks

  15. Anti-Drug antibody

    number and percentage of subjects tested ADA positive

    Time frame: During 32 weeks

07

Study locations

41 of 44 sites recruiting
  • Anqiing Municipal Hospital
    Anqing, Anhui 246004, China
    Not yet recruiting
    • · Contact0556-5223968
  • Wanbei Coal-Electricity Group General Hospital
    Suzhou, Anhui 234000, China
    Recruiting
    • Jiang Hui · Contact
  • China-Japan Friendship Hospital
    Beijing, Beijing Municipality 100029, China
    Recruiting
    • Yang Ting · Contact
  • The Affiliated Yongchuan Hospital of Chongqing Medical University
    Chongqing, Chongqing Municipality 402160, China
    Recruiting
    • Zhang tie feng · Contact023-85382120
  • Gansu Provincial People's Hospital
    Lanzhou, Gansu 730000, China
    Recruiting
    • Zhang Hong · Contact
  • The Third Hospital of Hebei Medical University
    Shijiazhuang, Hebei 050051, China
    Recruiting
    • Zhao Yun Xia · Contact
  • The Affiliated Hospital of North China University of Science and Technology
    Tangshan, Hebei 063000, China
    Recruiting
    • Yu Chang Li · Contact
  • Xingtai People's Hospital
    Xingtai, Hebei 054001, China
    Recruiting
    • Gao Zhi Guo · Contact
  • The First Affiliated Hospital of Hebei North University
    Zhangjiakou, Hebei 075000, China
    Recruiting
    • Liu Jian Hua · Contact
  • Daqing Oilfield General Hospital
    Daqing, Heilongjiang 163001, China
    Recruiting
    • Li Li · Contact
  • The Second Affiliated Hospital of Heilongjiang University of Chinese Medicine
    Harbin, Heilongjiang 150001, China
    Recruiting
    • Yang Shan Jun · Contact
  • The Third Affiliated Hospital of Qiqihar Medical University
    Qiqihar, Heilongjiang 161000, China
    Recruiting
    • jiang Yun Fei · Contact
  • Anyang People's Hospital
    Anyang, Henan 455000, China
    Recruiting
    • Jia Ming Yong · Contact
  • The First Affiliated Hospital of Henan University
    Kaifeng, Henan 475000, China
    Recruiting
    • Huang Zhi Ang · Contact
  • Sanmenxia Central Hospital
    Sanmenxia, Henan 472000, China
    Recruiting
    • Liu Kuan · Contact
  • Xinxiang First People's Hospital
    Xinxiang, Henan 453000, China
    Recruiting
    • Li Rong Kai · Contact
  • Yichang Central People's Hospital
    Yichang, Hubei 443003, China
    Recruiting
    • Xiong Xiao Qi · Contact
  • Huhhot First Hospital
    Hohhot, Inner Mongolia 010020, China
    Not yet recruiting
    • Song fei fang · Contact0471-5281222
  • The Affiliated Hospital of Inner Mongolia
    Hohhot, Inner Mongolia 010030, China
    Not yet recruiting
    • Gao jun zhen · Contact0471-3451027
  • Nanjing Jiangning Hospital
    Nanjing, Jiangsu 211100, China
    Recruiting
    • Zhang Xiu Wei · Contact
  • The Affiliated Hospital of Xuzhou Medical University
    Xuzhou, Jiangsu 221002, China
    Recruiting
    • Zhang Wen Hui · Contact
  • Xuzhou Mining Group General Hospital
    Xuzhou, Jiangsu 221006, China
    Recruiting
    • Zhao jie · Contact0516-85326063
  • Xuzhou Central Hospital
    Xuzhou, Jiangsu 221009, China
    Recruiting
    • Wu yan min · Contact0516-83956108
  • The First Affiliated Hospital of Nanchang University
    Nanchang, Jiangxi 330006, China
    Recruiting
    • Zuo Wei · Contact
  • The First Hospital of Jilin University
    Changchun, Jilin 130021, China
    Recruiting
    • Guo Li Ping · Contact
  • Jilin Central Hospital
    Jilin City, Jilin 132011, China
    Recruiting
    • Wang Yu Hong · Contact
  • Shengjing Hospital of China Medical University
    Shenyang, Liaoning 110004, China
    Recruiting
    • Zhao Li · Contact
  • The Fourth Affiliated Hospital of China Medical University
    Shenyang, Liaoning 110031, China
    Recruiting
    • Gu xiiu · Contact024-31365555
  • Ningxia Hui Autonomous Region People's Hospital
    Yinchuan, Ningxia 750002, China
    Recruiting
    • Zhuan Bing · Contact
  • Xi'an International Medical Center Hospital
    Xi'an, Shaanxi 710100, China
    Recruiting
    • Fu En Qing · Contact
  • Heze Municipal Hospital
    Heze, Shandong 274031, China
    Recruiting
    • Liu Xun Chao · Contact
  • Qilu Second Hospital of Shandong University
    Jinan, Shandong 250022, China
    Recruiting
    • Xu Shao Hua · Contact
  • The Affiliated Hospital of Jining Medical University
    Jining, Shandong 272029, China
    Recruiting
    • jiang Bo · Contact
  • Qingdao Municipal Hospital
    Qingdao, Shandong 266011, China
    Recruiting
    • Han Wei · Contact
  • Yantai Yuhuangding Hospital
    Yantai, Shandong 264000, China
    Recruiting
    • Zou Shen Chun · Contact
  • Zibo Central Hospital
    Zibo, Shandong 255036, China
    Recruiting
    • Yin Xin Da · Contact
  • Shanghai Pulmonary Hospital (Tongji University Affiliated Shanghai Pulmonary Hospital)
    Shanghai, Shanghai Municipality 200433, China
    Recruiting
    • Guo Jian · Contact
  • Yuncheng Central Hospital
    Yuncheng, Shanxi 044000, China
    Recruiting
    • Zhang Hai Xia · Contact
  • Chengdu Third People's Hospital
    Chengdu, Sichuan 610031, China
    Recruiting
    • Li Guo Ping · Contact
  • Chengdu Fifth People's Hospital
    Chengdu, Sichuan 611130, China
    Recruiting
    • Liu Xiao · Contact
  • Mianyang Central Hospital
    Mianyang, Sichuan 621000, China
    Recruiting
    • Xu Wei Guo · Contact
  • Affiliated Hangzhou First People's Hospital
    Hangzhou, Zhejiang 310006, China
    Recruiting
    • Wang li ming · Contact0571-56005600
  • The First Affiliated Hospital of Ningbo University
    Ningbo, Zhejiang 315010, China
    Recruiting
    • Ma hong ying · Contact0574-87085588
  • The Second Affiliated Hospital of Wenzhou Medical University
    Wenzhou, Zhejiang 325027, China
    Recruiting
    • Wu Li Qin · Contact
08

References and documents

Individual participant data

Plan to share: Yes

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Mar 2026 (actual). Primary completion is estimated for Oct 2027, 19 months after the start.

Of 137 industry-sponsored phase 2 interventional studies under Asthma, half reached primary completion within 16 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 23. This study's planned 19 months is above that.

Counting every sponsor, half of 199 studies reached it within 20 months; a quarter within 12 and three quarters within 41.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 27, 2026
First posted
Feb 11, 2026
StartActual
Mar 10, 2026
Primary completionEst.
Oct 25, 2027
CompletionEst.
Feb 28, 2028
Last update
Sep 10, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 10, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07403487
Lead sponsor
Nanjing RegeneCore Biotech Co., Ltd.
Responsible party
Sponsor
First posted
Feb 11, 2026
Start date
Mar 10, 2026
Primary completion
Oct 25, 2027 (estimated)
Completion
Feb 28, 2028 (estimated)
Last update
Sep 10, 2026

Study contacts

Guo Qian
Contact
guoqian@regenecore.com
+86-025-58608860

Oversight

FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: RC1416

Start the discussion